CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 97 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,324,797 | -25.0% | 4,902,943 | 0.0% | 0.00% | – |
| Q2 2023 | $8,433,062 | +13.6% | 4,902,943 | -0.2% | 0.00% | – |
| Q1 2023 | $7,421,730 | +1.2% | 4,915,053 | +7.2% | 0.00% | – |
| Q4 2022 | $7,337,154 | +11.5% | 4,585,721 | +1.1% | 0.00% | – |
| Q3 2022 | $6,580,000 | -29.2% | 4,537,961 | -10.6% | 0.00% | – |
| Q2 2022 | $9,294,000 | -33.4% | 5,078,387 | -2.8% | 0.00% | – |
| Q1 2022 | $13,945,000 | -37.0% | 5,222,886 | +2.2% | 0.00% | -100.0% |
| Q4 2021 | $22,118,000 | -21.2% | 5,107,991 | -7.4% | 0.00% | 0.0% |
| Q3 2021 | $28,078,000 | -17.2% | 5,516,321 | +3.0% | 0.00% | 0.0% |
| Q2 2021 | $33,917,000 | -5.9% | 5,358,085 | +15.0% | 0.00% | 0.0% |
| Q1 2021 | $36,027,000 | +87.4% | 4,660,798 | +58.8% | 0.00% | 0.0% |
| Q4 2020 | $19,221,000 | +1.3% | 2,934,424 | +2.8% | 0.00% | 0.0% |
| Q3 2020 | $18,980,000 | -14.1% | 2,854,188 | +7.6% | 0.00% | 0.0% |
| Q2 2020 | $22,093,000 | +6.3% | 2,652,335 | -2.1% | 0.00% | 0.0% |
| Q1 2020 | $20,789,000 | -7.0% | 2,710,539 | +0.8% | 0.00% | 0.0% |
| Q4 2019 | $22,350,000 | +16.1% | 2,689,604 | +3.1% | 0.00% | 0.0% |
| Q3 2019 | $19,258,000 | -35.7% | 2,609,498 | -2.3% | 0.00% | 0.0% |
| Q2 2019 | $29,973,000 | +15.6% | 2,671,374 | +10.8% | 0.00% | 0.0% |
| Q1 2019 | $25,929,000 | +17.9% | 2,412,019 | +65.7% | 0.00% | 0.0% |
| Q4 2018 | $21,985,000 | -52.6% | 1,455,924 | -41.9% | 0.00% | -50.0% |
| Q3 2018 | $46,343,000 | -4.2% | 2,504,987 | +18.3% | 0.00% | 0.0% |
| Q2 2018 | $48,400,000 | +16.2% | 2,117,265 | +44.6% | 0.00% | 0.0% |
| Q1 2018 | $41,648,000 | +64.3% | 1,463,883 | +21.9% | 0.00% | +100.0% |
| Q4 2017 | $25,355,000 | +21.5% | 1,201,111 | +4.6% | 0.00% | 0.0% |
| Q3 2017 | $20,864,000 | +45.7% | 1,148,206 | +24.2% | 0.00% | 0.0% |
| Q2 2017 | $14,323,000 | +0.7% | 924,138 | +12.2% | 0.00% | 0.0% |
| Q1 2017 | $14,223,000 | +62.6% | 823,531 | +3.5% | 0.00% | – |
| Q4 2016 | $8,748,000 | -28.9% | 795,999 | +1.4% | 0.00% | -100.0% |
| Q3 2016 | $12,303,000 | +224.2% | 784,646 | +111.2% | 0.00% | – |
| Q2 2016 | $3,795,000 | +27.9% | 371,522 | +61.5% | 0.00% | – |
| Q1 2016 | $2,968,000 | -28.6% | 230,056 | +15.5% | 0.00% | – |
| Q4 2015 | $4,156,000 | – | 199,137 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |